Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-12
2009-06-30
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
07553856
ABSTRACT:
A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable excipients and the use of omeprazole form C for treatment of gastrointestinal disorders are disclosed.
REFERENCES:
patent: 5314506 (1994-05-01), Midler et al.
patent: 6147103 (2000-11-01), Anousis et al.
patent: 6150380 (2000-11-01), Lovqvist et al.
patent: 6162816 (2000-12-01), Bohlin et al.
patent: 6268502 (2001-07-01), Milac et al.
patent: 6627646 (2003-09-01), Bakale et al.
patent: 0 005 129 (1979-10-01), None
patent: 98/28294 (1998-07-01), None
patent: 99/08500 (1999-02-01), None
patent: 00/02876 (2000-01-01), None
Brittain et al., “Polymorphism in Pharmaceutical Solids”, NY:Marcel Dekker, Inc., 1999, pp. 1-2, 185.
Muzaffar et al., “Polymorphism and Drug Availability”, J of Pharmacy (Lahore) (1979), 1(1), pp. 59-66.
Taday et al., “Using Terahertz Pulse, etc.,” J of Pharmaceutical Sciences, 92(4), 2003, pp. 831-838.
Wall et al., “Pharmaceutical Applications, etc.,” Pharmaceutical Manufacturing, 3(2), 1986, pp. 32-34.
Jain et al., “Polymorphism in Pharmacy” Indian Drugs, 1986, 23(6), pp. 315-329.
Otsuka et al., “Effect of Polymorphic Forms, etc.,” Chem. Pharm. Bull. 47(6), 1999, pp. 852-856.
Doelker et al. CA 132:325872, 2000.
Ulicky et al., “Comprehensive Dictionary of Physical Chemistry”, NY: PTR Prenctice Hall 1992, p. 21.
Doelker, english translation of S.T.P. Pharma Pratiques (1999), 9(5), 399-409, pp. 1-33.
Bernstein et al., “Polymorphism in Molecular Crystals”, Oxford: Clarendon Press, 2002, pp. 117, 118, 272 and 273.
Davidovich et al., “Detection of Polymorphism, etc.,” American Pharmaceutical REview, IN: Russell Pub., 2004, 7(1), pp. 10, 12, 14, 16 and 100.
Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, 198, Berline Heidelberg: Springer Verlag, 1998, pp. 164-208.
CMU Pharmaceutical polymorphism, interent p. 1-3 (2002) (print out Apr. 3, 2008).
Singhal et al., “Drug polymorphism, etc.,” Advanced drug delivery reviews 56, p. 335-347 (2004).
Rowland et al., “Clinical Pharmacokinetics, etc.,” 1995, p. 123.
Silverman, The Organic Chemistry of Drug Design and Drug Action, NY: Academic Press, 1993, 72-76.
Doelker, english translation of Ann. Pharm. Fr. 2002, 60: 161-176, pp. 1-39.
Ohishi et al., Structure of 5-Methoxy-2-{[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazole (Omeprazole), Acta Cryst., vol. C45, pp. 1921-1923 (1989).
Brittain, “Polymorphism in Pharmaceutical Solids”, NY Marcel Dekker, 1999, pp. 227-263.
US Pharmacopia, 1995, pp. 1843-1844.
Halbein et al., J. Pharm. Sci., 58 (1969) pp. 911-928.
Belcic Andreja C
Copar Anton
Kosak Alenka
Milac Natasa H
Ornik Brina
Lek Pharmaceuticals d.d.
Luedeka Neely & Graham P.C.
Morris Patricia L
LandOfFree
Crystalline form of omeprazole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of omeprazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of omeprazole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110597